The information in this section is intended for visitors outside the United States.
European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Gilead Sciences to Present at the Bernstein 31st Annual Strategic Decisions Conference on Thursday, May 28
Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19
2014 Annual Review